Further research by Han et al. demonstrated that 3-ILA exerts its anti-tumor effects by targeting the nuclear receptor RAR-related orphan receptor γt (RORγt) to inhibit T helper 17 cell differentiation, thereby downregulating the IL-17 signaling pathway (Han et al., 2023). The gene discussed is IL17A; the disease is neoplasm.